Aurion Biotech, Inc. has completed patient enrollment in its U.S. ASTRA Phase 3 study. The company develops regenerative cell therapies focused on restoring vision. Its broader goal involves working toward a future where blindness is eliminated. The ASTRA study evaluates AURN001 as a single-administration investigational regenerative cell therapy. The therapy targets corneal edema secondary to corneal endothelial dysfunction.
AURN001 could become the first cell therapy approved in the U.S. for this condition. The pivotal study continues to assess its efficacy and safety against a vehicle control. The company reached full enrollment across 12 U.S. clinical sites. Therefore, the milestone represents an important step toward the planned U.S. BLA submission.
Completing enrollment in our U.S. pivotal study marks a major milestone for Aurion and an important step toward our planned BLA submission. Building on our success in Japan, we remain committed to advancing a global solution for this unmet need.
“Completing enrollment in ASTRA is a shared achievement. Dosing our final patient in this study reflects the work of our investigators and site teams who executed with conviction, the patients who trusted us with their vision, and the cross-functional teams here at Aurion who cleared every obstacle along the way,” said Eris P. Jordan, OD, Chief Development Officer, Aurion Biotech. “The Phase 3 protocol was built to two standards at once: the regulatory expectations for a pivotal study, and the lived expectations of the patients it is designed to serve. Through a dedicated patient advisory board, we invited the community into the design process, and their input shaped both trial feasibility and the endpoints that matter most to patients living with this disease.”
AURN001 Targets Corneal Endothelial Disease
The global burden of corneal endothelial disease remains significant. At the same time, patients face limited access to donor tissue. Current surgical approaches can also involve considerable complexity. Consequently, these challenges highlight the need for scalable treatment options. AURN001 represents a potential first-in-class investigational combination therapy. The therapy targets corneal endothelial disease, including Fuchs dystrophy.
The treatment approach addresses several barriers affecting current care. These barriers include surgical complexity and limited donor tissue availability. Post-operative complications also remain an important consideration for patients and providers. Therefore, AURN001 could potentially expand treatment access for patients with limited options. The investigational therapy combines unmodified human corneal endothelial cells (neltependocel) with a rho-kinase inhibitor. The inhibitor used in AURN001 is Y-27632.
Aurion Biotech designed AURN001 to support corneal regeneration. The therapy uses an intracameral injection to deliver the treatment. The approach aims to restore corneal clarity and improve vision. Furthermore, its single-administration design could offer an alternative to more complex surgical approaches. The company continues to evaluate AURN001 through its pivotal U.S. clinical development program. The ASTRA Phase 3 study remains central to this development strategy.
Aurion Biotech Moves Toward Planned BLA Submission
The completion of ASTRA enrollment represents a significant development for Aurion Biotech. It also reflects progress across several areas of the AURN001 program. These areas include regulatory activities, quality operations, manufacturing, and clinical development. The company says its teams established this foundation from the beginning of the program.
“Completing enrollment in our U.S. pivotal study marks a major milestone for Aurion and an important step toward our planned BLA submission,” said Arnaud Lacoste, PhD, MBA, Chief Executive Officer and Chief Scientific Officer, Aurion Biotech. “This achievement reflects the strength of the foundation established across our regulatory, quality, manufacturing, and clinical teams from the outset of the program. Their collective expertise and execution enabled us to reach full enrollment on an accelerated timeline and brings us closer to delivering a scalable, transportable regenerative cell therapy for patients affected by corneal endothelial blindness. Building on our success in Japan, we remain committed to advancing a global solution for this significant unmet medical need.”
Aurion Biotech now has full enrollment across the 12 U.S. sites involved in ASTRA. The company views this milestone as progress toward its planned BLA submission. Meanwhile, the ongoing Phase 3 study will continue evaluating AURN001. The trial will assess both efficacy and safety compared with vehicle control. The program also builds on Aurion Biotech’s previous work in Japan. The company plans to continue developing AURN001 as a potential global treatment option.
As a result, the latest enrollment milestone moves AURN001 further through its clinical development pathway. It also brings Aurion Biotech closer to its stated goal of addressing corneal endothelial blindness. The company remains focused on developing a scalable and transportable regenerative cell therapy. AURN001 could potentially provide another treatment option for patients affected by corneal endothelial disease.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
